within Pharmacolibrary.Drugs.ATC.L;

model L01FF02
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 3.3333333333333333e-06,
    adminDuration  = 600,
    adminMass      = 200 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.006,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0032,
    k12             = 0.29,
    k21             = 0.29
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01FF02</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Pembrolizumab is a humanized monoclonal antibody that blocks the interaction between PD-1, a receptor on T cells, and its ligands, PD-L1 and PD-L2, thereby promoting immune-mediated anti-tumor activity. It is primarily used in the treatment of various cancers, including melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, classical Hodgkin lymphoma, and others. Pembrolizumab is FDA-approved for multiple cancer indications and is in active clinical use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult cancer patients (both sexes, broad adult age range) receiving intravenous pembrolizumab monotherapy.</p><h4>References</h4><ol><li><p>Rudin, CM, et al., &amp; Gupta, S (2023). Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors. <i>Journal for immunotherapy of cancer</i> 11(1) –. DOI:<a href=\"https://doi.org/10.1136/jitc-2022-005007\">10.1136/jitc-2022-005007</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36669791/\">https://pubmed.ncbi.nlm.nih.gov/36669791</a></p></li><li><p>Patnaik, A, et al., &amp; Tolcher, AW (2015). Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors. <i>Clinical cancer research : an official journal of the American Association for Cancer Research</i> 21(19) 4286–4293. DOI:<a href=\"https://doi.org/10.1158/1078-0432.CCR-14-2607\">10.1158/1078-0432.CCR-14-2607</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25977344/\">https://pubmed.ncbi.nlm.nih.gov/25977344</a></p></li><li><p>Freshwater, T, et al., &amp; Stone, JA (2017). Evaluation of dosing strategy for pembrolizumab for oncology indications. <i>Journal for immunotherapy of cancer</i> 5 43–None. DOI:<a href=\"https://doi.org/10.1186/s40425-017-0242-5\">10.1186/s40425-017-0242-5</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/28515943/\">https://pubmed.ncbi.nlm.nih.gov/28515943</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01FF02;
